Potent and selective, competitive motilin receptor antagonist (IC50 = 4.9 nM). Selective for the motilin receptor over a range of other receptors and ion channels. Inhibits motilin-induced duodenal muscle contractions in vitro. Also inhibits motilin-induced colonic and abdominal contractions in vivo. Orally active.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 556.71. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.8 mL||8.98 mL||17.96 mL|
|5 mM||0.36 mL||1.8 mL||3.59 mL|
|10 mM||0.18 mL||0.9 mL||1.8 mL|
|50 mM||0.04 mL||0.18 mL||0.36 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Sudo et al (2008) Oral administration of MA-2029, a novel selective and competitive motilin receptor antagonist, inhibits motilin-induced intestinal contractions and visceral pain in rabbits. Eur.J.Pharmacol. 581 296 PMID: 18164286
If you know of a relevant reference for MA 2029, please let us know.
View Related Products by Product Action
Keywords: MA 2029, supplier, MA2029, potent, selective, competitive, motilin, receptors, antagonists, Motilin, Receptors, Motilin, Receptors, Tocris Bioscience
Citations for MA 2029
Citations are publications that use Tocris products.
Currently there are no citations for MA 2029. Do you know of a great paper that uses MA 2029 from Tocris? If so please let us know.